BioSpace News Archive

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced one-year data from the ADAPT study (n=82), the first multi-national randomized controlled study comparing the performance of the MiniMed™ 780G advanced hybrid closed loop system1 (AHCL) against multiple daily injections (MDI) of insulin with an intermittently scanned CGM (isCGM).

Gestational diabetes and preeclampsia may be linked to slower biological development in infants, according to a new study funded by the Environmental influences on Child Health Outcomes Program (ECHO) at the National Institutes of Health.

Innovations in cancer treatment resulting from research conducted through the Florida Cancer Specialists & Research Institute, LLC (FCS) Phase 1 Drug Development Units and at FCS clinics throughout Florida were featured recently at two global gatherings sponsored by the American Society of Clinical Oncology (ASCO®).

Long-term exposure to air pollution is tied to an increased risk of having a heart attack or dying from heart disease — with the greatest harms impacting under-resourced communities, new Kaiser Permanente research shows.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Cytokinetics, Incorporated announced three poster presentations at the American College of Cardiology 72nd Annual Scientific Session taking place in New Orleans, LA from March 4, 2023 – March 6, 2023.

TransMedics Group, Inc. announced that on February 20, 2023, TransMedics granted non-qualified stock options to purchase an aggregate of 72,774 shares of its common stock to seven employees and an aggregate of 17,092 restricted stock units to three employees, each as a material inducement for each employee’s entry into employment with TransMedics.

Bryn Pharma LLC announced positive pharmacokinetic/pharmacodynamic and safety data for its investigational 13.2mg intranasal epinephrine spray, UTULY™.

Exicure, Inc., an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, announced the closing of the previously-announced private placement transaction with CBI USA, Inc. effective February 24, 2023.

ASLAN to receive $20 million in financing with the potential to receive up to an additional $80 million for an aggregate of $100 million to continue advancing the clinical development of eblasakimab and farudodstat.